Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Albers

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Respiratory Medicine|June 21, 2019
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibilityMarc Humbert, Frank C Albers, Daniel J Bratton, et al.
Oncogene|November 3, 2009
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathwayB Markova, C Albers, F Breitenbuecher, et al.
Journal of Neuro-Oncology|December 1, 2022
Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastasesElaine A C Albers, Michiel B de Ruiter, Lonneke V van de Poll-Franse, et al.
The Korean Journal of Internal Medicine|May 26, 2020
Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studiesMi-Kyeong Kim, Hae-Sim Park, Choon-Sik Park, et al.
Plos One|May 3, 2014
The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trialDenis E O'Donnell, François Maltais, Janos Porszasz, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 17, 2017
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL studyFrank C Albers, Hana Müllerová, Necdet B Gunsoy, et al.
ERJ Open Research|September 23, 2020
Response to mepolizumab treatment is sustained across 4-weekly dosing periodsIan D Pavord, Eugene R Bleecker, Roland Buhl, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|September 17, 2024
Self-perceived cognitive impairment in the first year after breast cancer and the identification of at-risk patientsA S Huberts, E A C Albers, K M de Ligt, et al.
Respiratory Medicine|February 1, 2017
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparisonSarah M Cockle, Gillian Stynes, Necdet B Gunsoy, et al.
Physical Review Letters|April 20, 2004
Extended X-ray absorption fine structure measurements of laser-shocked V and Ti and crystal phase transformation in TiB Yaakobi, D D Meyerhofer, T R Boehly, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Respiratory Medicine|June 21, 2019
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibilityMarc Humbert, Frank C Albers, Daniel J Bratton, et al.
Oncogene|November 3, 2009
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathwayB Markova, C Albers, F Breitenbuecher, et al.
Journal of Neuro-Oncology|December 1, 2022
Neurocognitive functioning after Gamma Knife and LINAC stereotactic radiosurgery in patients with brain metastasesElaine A C Albers, Michiel B de Ruiter, Lonneke V van de Poll-Franse, et al.
The Korean Journal of Internal Medicine|May 26, 2020
Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studiesMi-Kyeong Kim, Hae-Sim Park, Choon-Sik Park, et al.
Plos One|May 3, 2014
The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trialDenis E O'Donnell, François Maltais, Janos Porszasz, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|June 17, 2017
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL studyFrank C Albers, Hana Müllerová, Necdet B Gunsoy, et al.
ERJ Open Research|September 23, 2020
Response to mepolizumab treatment is sustained across 4-weekly dosing periodsIan D Pavord, Eugene R Bleecker, Roland Buhl, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|September 17, 2024
Self-perceived cognitive impairment in the first year after breast cancer and the identification of at-risk patientsA S Huberts, E A C Albers, K M de Ligt, et al.
Respiratory Medicine|February 1, 2017
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparisonSarah M Cockle, Gillian Stynes, Necdet B Gunsoy, et al.
Physical Review Letters|April 20, 2004
Extended X-ray absorption fine structure measurements of laser-shocked V and Ti and crystal phase transformation in TiB Yaakobi, D D Meyerhofer, T R Boehly, et al.
Pageof 13